A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis

Trial Profile

A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms GO-BACK
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 31 Aug 2017 Planned End Date changed from 19 Sep 2022 to 3 Oct 2022.
    • 31 Aug 2017 Planned primary completion date changed from 7 Mar 2022 to 18 Apr 2022.
    • 31 Aug 2017 Planned initiation date changed from 17 Oct 2017 to 31 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top